Anti-death strategies against oxidative stress in grafted mesenchymal stem cells

Histology and Histopathology

Volumn 28, Issue 12, 2013, Pages 1529-1536

  Chang, Woochul ^a   Song, Byeong Wook ^b   Moon, Jae Youn ^c   Cha, Min Ji ^d   Ham, Onju ^e   Lee, Se Yeon ^e   Choi, Eunmi ^e   Choi, Eunhyun ^f   Hwang, Ki Chul ^e,f  

^a Pusan National University   (South Korea)

^b Bupyeong gu   (South Korea)

^c CHA University   (South Korea)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

Anoikis; Mesenchymal stem cells; Myocardial infarction; Reactive oxygen species

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ANOIKIS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

ANOIKIS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84888099766     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Andreadou I., Iliodromitis E.K., Farmakis D. and Kremastinos D.T. (2009). To prevent, protect and save the ischemic heart: antioxidants revisited. Expert Opin. Ther. Targets 13, 945-956.
2. Angelos M.G., Kutala V.K., Torres C.A., He G., Stoner J.D., Mohammad M. and Kuppusamy P. (2006). Hypoxic reperfusion of the ischemic heart and oxygen radical generation. Am. J. Physiol. Heart Circ. Physiol. 290, H341-H347.
3. Attwell S., Roskelley C. and Dedhar S. (2000). The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 19, 3811-3815.
4. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A. and Hoffman R. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48.
5. Blanchetot C. and Boonstra J. (2008). The ROS-NOX connection in cancer and angiogenesis. Crit. Rev. Eukaryot. Gene Expr. 18, 35-45.
6. Bonomini F., Tengattini S., Fabiano A., Bianchi R. and Rezzani R. (2008). Atherosclerosis and oxidative stress. Histol. Histopathol. 23, 381-390.
7. Brown M.C. and Turner C.E. (2004). Paxillin: adapting to change. Physiol. Rev. 84, 1315-1339.
8. Cao Y.J., Shibata T. and Rainov N.G. (2001). Hypoxia-inducible transgene expression in differentiated human NT2N neurons--a cell culture model for gene therapy of postischemic neuronal loss. Gene Ther. 8, 1357-1362.
9. Carrière A., Ebrahimian T.G., Dehez S., Augé N., Joffre C., André M., Arnal S., Duriez M., Barreau C., Arnaud E., Fernandez Y., Planat-Benard V., Lévy B., Pénicaud L., Silvestre J.S. and Casteilla L. (2009). Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. Arterioscler. Thromb. Vasc. Biol. 29, 1093-1099.
10. Chiarugi P. and Buricchi F. (2007). Protein tyrosine phosphorylation and reversible oxidation: Two cross-talking posttranslation modifications. Antioxid. Redox Signal. 9, 1-24.
11. Chiarugi P. and Fiaschi T. (2007). Redox signaling in anchoragedependent cell growth. Cell. Signal. 19, 672-682.
12. Chiarugi P. and Giannoni E. (2008). Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 76, 1352-1364.
13. Drowley L., Okada M., Beckman S., Vella J., Keller B., Tobita K. and Huard J. (2010). Cellular antioxidant levels influence muscle stem cell therapy. Mol. Ther. 18, 1865-1873.
14. Ferdinandy P., Schulz R. and Baxter G.F. (2007). Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 59, 418-458.
15. Fonarow G.C. (2000). Heart failure: recent advances in prevention and treatment. Rev. Cardiovasc. Med. 1, 25-33.
16. Fraser J.K., Schreiber R.E., Zuk P.A. and Hedrick M.H. (2004). Adult stem cell therapy for the heart. Int. J. Biochem. Cell Biol. 36, 658-666.
17. Frisch S.M. and Francis H. (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619-626.
18. Frisch S.M. and Screaton R.A. (2001). Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555-562.
19. Gartner S. and Kaplan H.S. (1980). Long-term culture of human bone marrow cells. Proc. Natl. Acad. Sci. USA. 77, 4756-4759.
20. Gervais F.G., Thornberry N.A., Ruffolo S.C., Nicholson D.W. and Roy S. (1998). Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide. J. Biol. Chem. 273, 17102-17108.
21. Gilmore A.P. (2005). Anoikis. Cell Death Differ. 12, 1473-1477.
22. Griendling K.K., Sorescu D. and Ushio-Fukai M. (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494-501.
23. Gulati R. and Simari R.D. (2007). Cell therapy for acute myocardial infarction. Med. Clin. North Am. 91, 769-785.
24. Guo J., Lin G.S., Bao C.Y., Hu Z.M. and Hu M.Y. (2007). Antiinflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 30, 97-104.
25. Hagiwara M., Shen B., Chao L. and Chao J. (2008). Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum. Gene Ther. 19, 807-819.
26. Haider H. Kh. and Ashraf M. (2005). Bone marrow stem cell transplantation for cardiac repair. Am. J. Physiol. Heart Circ. Physiol. 288, H2557-H2567.
27. Huang Q., Shen H.M., Shui G., Wenk M.R. and Ong C.N. (2006). Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res. 66, 5807-5815.
28. Kamata H., Honda S., Maeda S., Chang L., Hirata H. and Karin M. (2005). Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661.
29. Katritsis D.G., Sotiropoulou P.A., Karvouni E., Karabinos I., Korovesis S., Perez S.A., Voridis E.M. and Papamichail M. (2005). Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter. Cardiovasc. Interv. 65, 321-329.
30. Kizaki M., Xian M., Sagawa M. and Ikeda Y. (2006). Induction of apoptosis via the modulation of reactive oxygen species (ROS) production in the treatment of myeloid leukemia. Curr. Pharm. Biotechnol. 7, 323-329.
31. Kumar S., Chanda D. and Ponnazhagan S. (2008). Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 15, 711-715.
32. Kulkarni A.C., Kuppusamy P. and Parinandi N. (2007). Oxygen, the lead actor in the pathophysiologic drama: enactment of the trinity of normoxia, hypoxia, and hyperoxia in disease and therapy. Antioxid. Redox Signal. 9, 1717-1730.
33. Legate K.R., Montañez E., Kudlacek O. and Fässler R. (2006). ILK, PINCH and parvin: the tIPP of integrin signalling. Nat. Rev. Mol. Cell Biol. 7, 20-31.
34. Leslie N.R. (2006). The redox regulation of PI 3-kinase-dependent signaling. Antioxid. Redox Signal. 8, 1765-1774.
35. Li J.M. and Shah A.M. (2004). Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R1014-R1030.
36. Lloyd-Jones D.M. (2001). The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr. Cardiol. Rep. 3, 184-190.
37. Melo L.G., Pachori A.S., Kong D., Gnecchi M., Wang K., Pratt R.E. and Dzau V.J. (2004). Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation 109, 2386-2393.
38. Memon I.A., Sawa Y., Fukushima N., Matsumiya G., Miyagawa S., Taketani S., Sakakida S.K., Kondoh H., Aleshin A.N., Shimizu T., Okano T. and Matsuda H. (2005). Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J. Thorac. Cardiovasc. Surg. 130, 1333-1341.
39. Mias C., Trouche E., Seguelas M.H., Calcagno F., Dignat-George F., Sabatier F., Piercecchi-Marti M.D., Daniel L., Bianchi P., Calise D., Bourin P., Parini A. and Cussac D. (2008). Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 26, 1749-1757.
40. Michel J.B. (2003). Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler. Thromb. Vasc. Biol. 23, 2146-2154.
41. Min J.Y., Yang Y., Sullivan M.F., Ke Q., Converso K.L., Chen Y., Morgan J.P. and Xiao Y.F. (2003). Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J. Thorac. Cardiovasc. Surg. 125, 361-369.
42. Mitra S. K, Hanson D.A. and Schlaepfer D.D. (2005). Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6, 56-68.
43. Mylotte L.A., Duffy A.M., Murphy M., O'Brien T., Samali A., Barry F. and Szegezdi E. (2008). Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. Stem Cells 26, 1325-1336.
44. Nekanti U., Rao V.B., Bahirvani A.G., Jan M., Totey S. and Ta M. (2010). Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Stem Cells Dev. 19, 117-130.
45. Nelson T.J., Martinez-Fernandez A. and Terzic A. (2010). Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat. Rev. Cardiol. 7, 700-710.
46. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A. and Anversa P. (2001). Bone marrow cells regenerate infarcted myocardium. Nature 410, 701-705.
47. Oshima Y., Fujio Y., Nakanishi T., Itoh N., Yamamoto Y., Negoro S., Tanaka K., Kishimoto T., Kawase I. and Azuma J. (2005). STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc. Res. 65, 428-435.
48. Parson J.T. (2003). Focal adhesion kinase: the first ten years. J. Cell Sci. 116, 1409-1416.
49. Pelegrin P. and Surprenant A. (2009). Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 28, 2114-2127.
50. Penn M.S. and Mangi A.A. (2008). Genetic enhancement of stem cell engraftment, survival, Circ. Res. 102, 1471-1482.
51. Powers S.K. and Jackson M.J. (2008). Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol. Rev. 88, 1243-1276.
52. Psaltis P.J., Zannettino A.C., Worthley S.G. and Gronthos S. (2008). Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 26, 2201-2210.
53. Robey T.E., Saiget M.K., Reinecke H. and Murry C.E. (2008). Systems approaches to preventing transplanted cell death in cardiac repair. J. Mol. Cell. Cardiol. 45, 567-581.
54. Rodrigues M., Turner O., Stolz D., Griffith L.G. and Wells A. (2012). Production of reactive oxygen species by multipotent stromal cells/mesenchymal stem cells upon exposure to fas ligand. Cell Transplant. 21, 2171-2187.
55. Sáenz-Morales D., Conde E., Escribese M.M., García-Martos M., Alegre L., Blanco-Sánchez I. and García-Bermejo M.L. (2009). ERK1/2 mediates cytoskeleton and focal adhesion impairment in proximal epithelial cells after renal ischemia. Cell. Physiol. Biochem. 23, 285-294.
56. Salsmann A., Schaffner-Reckinger E., Kabile F., Plancon S. and Kieffer N. (2005). A new functional role of the fibrinogen RGD motif as the molecular switch that selectively triggers integrin aIIbh3-dependent RhoA activation during cell spreading. J. Biol. Chem. 280, 33610-33619.
57. Schmidt-Lucke C., Rössig L., Fichtlscherer S., Vasa M., Britten M., Kämper U., Dimmeler S. and Zeiher A.M. (2005). Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111, 2981-2987.
58. Schuleri K.H., Boyle A.J. and Hare J.M. (2007). Mesenchymal stem cells for cardiac regenerative therapy. Handb. Exp. Pharmacol. 180, 195-218.
59. Segers V.F. and Lee R.T. (2008). Stem-cell therapy for cardiac disease. Nature 451, 937-942.
60. Simon H.U., Haj-Yehia A. and Levi-Schaffer F. (2000). Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5, 415-418.
61. Song H., Chang W., Lim S., Seo H.S., Shim C.Y., Park S., Yoo K.J., Kim B.S., Min B.H., Lee H., Jang Y., Chung N. and Hwang K.C. (2007). Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 25, 1431-1438.
62. Song H., Cha M.J., Song B.W., Kim I.K., Chang W., Lim S., Choi E.J., Ham O., Lee S.Y., Chung N., Jang Y. and Hwang K.C. (2010). Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells 28, 555-563.
63. Sonoda Y., Kasahara T., Yokota-Aizu E., Ueno M. and Watanabe S. (1997). A suppressive role of p125FAK protein tyrosine kinase in hydrogen peroxide-induced apoptosis of T98G cells. Biochem. Biophys. Res. Commun. 241, 769-774.
64. Sonoda Y., Matsumoto Y., Funakoshi M., Yamamoto D., Hanks S.K. and Kasahara T. (2000). Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J. Biol. Chem. 275, 16309-16315.
65. Swijnenburg R.J., Tanaka M., Vogel H., Baker J., Kofidis T., Gunawan F., Lebl D.R., Caffarelli A.D., de Bruin J.L., Fedoseyeva E.V. and Robbins R.C. (2005). Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112, I166-I172.
66. Tian H., Lu Y., Shah S.P., Wang Q. and Hong S. (2012). 14S,21Rdihydroxy-docosahexaenoic acid treatment enhances mesenchymal stem cell amelioration of renal ischemia/reperfusion injury. Stem Cells Dev. 21, 1187-1199.
67. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J. and Kessler P.D. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93-98.
68. Turrens J.F. (1997). Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 17, 3-8.
69. Vertesaljai M., Piroth Z., Fontos G., Szantho G., Lueff S., Reti M., Masszi T., Ablonczy L., Juhasz E.D., Simor T., Turner M.S. and Andreka P. (2008). Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail. Rev. 13, 227-244.
70. Wang G., Hazra T.K., Mitra S., Lee H.M. and Englander E.W. (2000). Mitochondrial DNA damage and a hypoxic response are induced by CoCl(2) in rat neuronal PC12 cells. Nucleic Acids Res. 28, 2135-2140.
71. Wang Q., Zhu H., Zhou W.G., Guo X.C., Wu M.J., Xu Z.Y., Jiang J.F., Shen C. and Liu H.Q. (2013). N-Acetylcysteine-pretreated human embryonic mesenchymal stem cell administration protects against bleomycin-induced lung injury. Am. J. Med. Sci. 346, 113-122.
72. Xia M., Wang D., Wang M., Tashiro S., Onodera S., Minami M. and Ikejima T. (2004). Dracorhodin perchlorate induces apoptosis via activation of caspases and generation of reactive oxygen species. J. Pharmacol. Sci. 95, 273-283.
73. Yao E.H., Yu Y. and Fukuda N. (2006). Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr. Pharm. Biotechnol. 7, 101-108.
74. Zhang W., Su X., Gao Y., Sun B., Yu Y., Wang X. and Zhang F. (2009). Berberine protects mesenchymal stem cells against hypoxiainduced apoptosis in vitro. Biol. Pharm. Bull. 32, 1335-1342.
75. Zhu Y., Liu T., Song K., Fan X., Ma X. and Cui Z. (2008). Adiposederived stem cell: a better stem cell than BMSC. Cell Biochem. Funct. 26, 664-675.
76. Ziegler W.H., Liddington R.C. and Critchley D.R. (2006). The structure and regulation of vinculin. Trends Cell Biol. 16, 453-460.